Pegpleranib

Drug Profile

Pegpleranib

Alternative Names: Anti-PDGF pegylated aptamer; Anti-PDGF-B aptamer; E-10030; E01AJ; Fovista; OAP-030; Pegpleranib sodium; X01E

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Archemix Corporation
  • Developer National Eye Institute; OphthoTech Corporation
  • Class Eye disorder therapies; Oligonucleotides; Peptide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Wet age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase I/II Von Hippel-Lindau disease

Most Recent Events

  • 12 Dec 2016 Adverse events data from the OPH-1002 and OPH-1003 trials in Wet age-related macular degeneration (Combination therapy, In adults, In the elderly, Treatment-naive) released by OphthoTech Corporation
  • 12 Dec 2016 Top-line efficacy data from the OPH-1002 and OPH-1003 trials in Wet age-related macular degeneration (Combination therapy, In adults, In the elderly, Treatment-naive) released by Novartis
  • 01 Dec 2016 OphthoTech Corporation terminates a phase II trial in Wet age-related macular degeneration (Combination therapy, In adults, In the elderly) in USA (Intravitreous) (NCT02387957)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top